Эффективность применения омега-3 полиненасыщенных жирных кислот для первичной и вторичной профилактики сердечно-сосудистых заболеваний: современное состояние проблемы


Гиляревский С.Р.

В обзоре обосновывается целесообразность широкого профилактического и лечебного применения ?-3 полиненасыщенных жирных кислот (?-3 ПНЖК) при различных сердечно-сосудистых заболеваниях (ССЗ). Представлены результаты эпидемиологических исследований, свидетельствующие о положительном влиянии ?-3 ПНЖК на риск развития осложнений ССЗ. Рассматриваются результаты многочисленных клинических исследований, посвященных оценке эффективности применения ?-3 ПНЖК для первичной и вторичной профилактики ишемической болезни сердца, после стентирования коронарных артерий, при нарушениях ритма сердца, сердечной недостаточности, дислипидемиях. Результаты ряда исследований подтверждают преимущества лекарственных препаратов, содержащих ?-3 ПНЖК, в отношении как степени частоты, так и клинической эффективности по сравнению с другими их источниками.

Литература


1. Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. J Am Coll Cardiol 2009;54:585–94.


2. Lavie CJ, Milani RV. Fish oils. Cardiovascular Drug Therapy. Philadelphia: Saunders, 1996:1608–13.


3. Lee JH, O’Keefe H, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83:324–32.


4. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205–09.


5. Albert CM, Hennekens CH, O’Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23–28.


6. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIP revenzione trial Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999;354:447–55.


7. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis [published correction appears in Lancet 2007;370:220. Lancet2007;369:1090–98.


8. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223–30.


9. Kris-Etherton PM, Harris WS, Appel LJ, for the American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease [published correction appears in Circulation 2003;107:512]. Circulation 2002;106:2747–57.


10. Sinclair HM. The diet of Canadian Indians and Eskimos. Proc Nutr Soc 1953;12:69–82.


11. Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand 1972;192:85–94.


12. Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. Adv Nutr Res 1980;3:1–22.


13. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975;28:958–66.


14. William H. Omega-3 fatty acids: the “Japanese” factor? J Am Coll Cardiol 2008;52:425–27.


15. Harris WS, Poston WC, Haddock CK. Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 2007;193:1–10.


16. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet And Reinfarction Trial (DART). Lancet 1989;2:757–61.


17. Macchia A, Levantesi G, Franzosi MG, et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail 2005;7:904–09.


18. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897–903.


19. Senges S for the OMEGA Study Group. Randomized trial of omega-3 fatty acids on top of modern therapy after acute myocardial infarction: the OMEGA trial. Oral presentation at: Annual Scientific Sessions of the American College of Cardiology; March 2009;Orlando, FL.


20. Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab 2007;32:619–34.


21. Kromhout D, Gitay EJ, Geleijnse JM, et al. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med2010;363(21):2015–26.


22. Gajos G, Rostoff P, Undas A, et al. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol2010;55:1671–78.


23. Sekikawa A, Ueshima H, Kadowaki T, et al. Less subclinical atherosclerosis in Japanese men in Japan than in white men in the United States in the post–World War II birth cohort. Am JEpidemiol 2007;165:617–24.


24. Sekikawa A, Curb JD, Ueshima H, et al. Marinederived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol2008;52:417–24.


25. Anand RG, Alkadri M, Lavie CJ, et al. The role of fish oil in arrhythmia prevention. J Cardiopulm Rehabil 2008;28:92–98.


26. Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol 2006;98:501–601.


27. Christensen JH, Gustenhoff P, Korup E, et al. Effect of fish oil on heart rate viability in survivors of myocardial infarction: a double blind randomized controlled trial. Br Med J 1996;312:677–78.


28. O’Keefe JH Jr, Abuissa H, Sastre A, et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate viability in men with healed myocardial infarctions and depressed ejection fractions. Am JCardiol 2006;97:1127–30.


29. Geelen A, Brouwer IA, Schouten EG, et al. Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. AmJ Clin Nutr 2005;81:416–20.


30. Mozaffarian D, Prineas RJ, Stein PK, et al. Dietary fish and n-3 fatty acid intake and cardiac electrocardiographic parameters in humans. J AmColl Cardiol 2006;48:478–84.


31. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884–91.


32. Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005;112:2762–68.


33. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613–19.


34. Calo L, Bianconi L, Colicicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723–28.


35. Crystal E, Garfinkle MS, Conolly SS, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2004;4:CD003611.


36. Mozaffarian D, Bryson CL, Lemaitre RN, et al. Fish intake and risk of incident heart failure. J AmColl Cardiol 2005;45:2015–21.


37. Yamagishi K, Nettleton JA, Folsom AR. Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J2008;156:967–74.


38. Yamagishi K, Iso H, Date C, et al. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women. J Am Coll Cardiol 2008;52:988–96.


39. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997;94:4318–23.


40. Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferators-activated receptors. Mol Cell 1999;3:397–403.


41. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093–129.


42. Duda MK, O’Shea KM, Lei B, et al. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res 2007;76:303–10.


43. Neschen S, Morino K, Rossbacker JC, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptorgamma-dependent mechanism in mice. Diabetes2006;55:924–28.


44. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res2005;96:939–49.


45. Itoh M, Suganami T, Satoh N, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb VascBiol 2007;27:1918–25.


46. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through. Nat Med 2005;11:1096–103.


47. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007;380:24–30.


48. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improved body weight in severe heart failure. J Heart Lung Transplant 2006;25:834–38.


49. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006;98:71–76.


50. Bays H. Rationale for prescription omega-3-acid ethylester therapy for hypertriglyceridemia: a primer for clinicians. Drugs Today (Barc)2008;44:205–46.


51. Bays H, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther2008;6:391–409.


52. von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res2007;73:310–15.


53. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation2002;106:2747–57.


54. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65Suppl:1645–54.


55. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409–35.


56. Huang B, Wu P, Bowker-Kinley MM, et al. Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferators activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 2002;51:276–83.


57. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385–91.


58. Davidson MH, Stein EA, Bayes HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/day to simvastatin 40 mg/day in hypertriglyceridemic patients: an 8-week randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354–67.


59. Harris WS, Jacobson TA. Omega-3 fatty acids. In: Ballantyne CM, editor. Clinical Lipidology: A Companion to Braunwald’s Heart Disease. Philadelphia, PA: Saunders, an imprint of Elsevier Inc, 2009:326–38.


60. USDA Agricultural Research Service. Nutrient Data Laboratory. Available at: http://www.ars.usda.gov/nutrientdata. AccessedJanuary 23, 2008.


61. Conquer JA, Holub BJ. Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 1997;32:341–45.


62. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44:455–63.


63. Din JN, Harding SA, Valerio CJ, et al. Dietary intervention with oil rich fish reduces plateletmonocyte aggregation in man. Atherosclerosis 2008;197:290–96.


64. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med2002;346:1113–18.


65. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006;9:95–104.


66. Harris WS, Kris-Etherton PM, Harris KA. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep 2008;10:503–09.


67. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA2001;285:2486–97.


68. World Health Organization. Diet, Nutrition, and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation. Technical report No. 916. Geneva: World Health Organization, 2003.


69. DeBacker G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601–10.


70. UK Scientific Advisory Committee on Nutrition. Advice on Fish Consumption Benefits and Risks. London: The Stationery Office, 2004.


71. Franz MJ, Bantle JP, Beebe CA, et al. Nutrition principles and recommendations in diabetes. Diabetes Care 2004;27(1):36–46.


72. Harris WS. The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr2008;87:1997–2002.


Похожие статьи


Бионика Медиа